Published in final edited form as:

Curr Opin Allergy Clin Immunol. 2011 December ; 11(6): 539–544. doi:10.1097/ACI.0b013e32834cb8fa.

T Regulatory Cells in Primary Immune Deficiencies

James W. Verbsky, M.D., Ph.D.¹ and Talal A. Chatila, M.D., M.Sc.²

¹Associate Professor of Pediatrics, Division of Rheumatology, Medical College of Wisconsin, Milwaukee WI 53211

²Professor of Pediatrics, UCLA. Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles CA 90095

Abstract

Purpose of the review—To summarize studies on the development and function of T regulatory cells in primary immune deficiencies.

Recent findings—Primary immune deficiencies are associated with high rates of autoimmunity. T regulatory (T_R) cells, which are critical to the control of autoimmunity, appear involved in the pathogenesis of PID-related autoimmunity. A number of PIDs, including Omenn's syndrome and Wiskott Aldrich Syndrome, have been associated with impaired production and/or function of thymus-derived (natural) T_R cells. Recently defined primary immunodeficiencies, including Stim1 deficiency, IL-10 receptor deficiency, and xIAP deficiency, have been associated with defects in T_R cells. De novo generated T_R cells from peripheral CD4⁺ conventional T cells is impaired in the hyper IgE syndrome.

Summary—Gene defects underlying PIDs may also compromise the T_R cell, leading to breakdown of peripheral tolerance.

Keywords

Foxp3; Natural Regulatory T cells and Induced Regulatory T cells; Autoimmunity; IL-10 and IL-10 Receptor Deficiency; STAT3; Hyper IgE Syndrome; Omenn's Syndrome

Introduction

The maintenance of peripheral tolerance is critically dependent on natural CD4⁺CD25⁺ T regulatory (nT_R) cells, which act to control the magnitude of immune responses to foreign antigens and to prevent autoimmunity [1–3]. The majority of nT_R cells are generated in the thymus as a committed regulatory cell population that expresses the lineage-specific transcription factor Foxp3 and are specific for self-antigens [4–6]. Foxp3⁺ T_R cells can be generated *in vitro* from Foxp3-negative CD4 lymphocytes by TCR activation of CD4 cells in the presence of TGF-β and IL-2 [7–9]. Induced Foxp3⁺ T_R (iT_R) cells are also generated *in vivo* from peripheral Foxp3[−] CD4⁺ cells resulting in a population of cells that have regulatory properties but with a distinct TCR repertoire. nT_R and iT_R act in synergy to induce peripheral tolerance [9–11]. While nT_R cells are phenotypically stable, some iT_R cell

Corresponding Author: James W. Verbsky M.D., Ph.D., Department of Pediatrics, Medical College of Wisconsin, Phone: 414-262-6701, Fax: 414-266-6695, jverbsky@mcw.edu.

Conflict of interest:

The authors acknowledge grant support by the National Institutes of Health to T.A.C. (5R01AI085090 and 5R01AI073731) and J.W.V. (1K08AI072023)

populations can lose expression of Foxp3 and become effector cells, including Th1 and Th17 cells [10–14]. Thus Foxp3⁺ T_R cells likely consist of dedicated Foxp3⁺ nT_R cells as well as a population of iT_R cells with plasticity. Numerous suppressive mechanisms for T_R cells have been demonstrated, such as CTLA-4 engagement of B7 molecules on target cells, expression of immunosuppressive cytokines such as IL-10, TGF- β and IL-35, cytotoxicity of target cells through the perforin/granzyme pathway, induction of indoleamine 2,3-dioxygenase (IDO) and the catabolism of tryptophan in target cells, as well as consumption of adenosine by expression of CD73 (Table 1) [15–24]

Immune deficiency versus immune dysregulation; opposite ends of the immune spectrum

A balanced adaptive immune response ensures protection against pathogens while preventing immune responses to self and autoimmunity. Genetic defects that disrupt this homeostatic process results in a spectrum of disorders with varying degrees of immune deficiency, characterized by susceptibility to infections, and immune dysregulation, characterized by autoimmune responses (Table 2). Severe combined immunodeficiency can be thought of at one end of the spectrum and is characterized by a complete lack of an adaptive immune response, resulting in severe life threatening infections from bacteria, fungi, and viruses within the first year of life. Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX), the clinical syndrome resulting from genetic mutations in Foxp3⁺, represents the opposite end of the spectrum, presenting with uncontrolled autoimmune response from birth. However, these are pure archetypical forms, and more commonly patients with PID express features of both immune deficiency and autoimmunity. This review will address the role of T_R cells in autoimmune manifestations of patients with known primary immune deficiencies.

Primary defects in T_R cells. IPEX and CD25 deficiency

Although the existence of T cell populations that suppress immune responses have been postulated and studied for decades, the discovery that mutations in the FOXP3 gene result in IPEX provided proof for the first time that these suppressive populations did indeed exist [25–27]. This X-linked disease presents very early in life with progressive bowel inflammation and failure to thrive. In addition, affected infants experience autoimmune diabetes mellitus, thyroiditis, Addison's disease, severe food allergies, eczema, and autoimmune cytopenias. Although an increased susceptibility to infections is reported in this syndrome, it is difficult to determine if this is due to a defect in controlling infections or due to secondary causes due to the overall ill health of these infants or due to the immunosuppressive mediations that must be used to treat these infants. Hematopoietic stem cell transplant is curative therapy, and full engraftment is not necessary to provide a cure. This is supported by extensive data that have demonstrated that Foxp3 is essential for the generation, maintenance, and function of T regulatory cells, and that these cells act in a dominant manner to suppress immune responses [3].

One of the defining characteristics of T_R cells is the expression of CD25, the high affinity IL-2 receptor, and this marker was the first to define the Foxp3⁺ T_R cell population [28]. Thus it was not surprising that deficiency in this protein resulted in a syndrome with many features of IPEX. For example, the initial description of CD25 deficiency demonstrated a syndrome that included severe immune enteropathy, eczema, and lymphoproliferation [29]. We have described an additional case of CD25 deficiency in a child with early onset diabetes mellitus, thyroiditis, and aggressive autoimmune hemolytic anemia in addition to severe enteropathy and eczema [16]. These reports highlight several features of IPEX or CD25 deficiency. First, inflammatory responses at sites of constant microbial exposure, sites

where iT_R cells are most effectively induced and particularly enriched, such as the skin and gut, appears to be universal in these disorders. Secondly, some of the other manifestations of IPEX may vary depending on the individual, as may the severity of symptoms as has recently been shown in patients with point mutations in Foxp3 [30]. Although endocrinopathies are common in IPEX, they are not seen in every individual, which may explain why the initial description of CD25 deficiency lacked endocrinopathies.

Importantly, patients with CD25 deficiency exhibit several unique features not seen in IPEX, namely chronic herpetic viral infections and an increased susceptibility to infections [16;29]. These results provide unique insights into the function of CD25 and IL-2, and demonstrate that this important cytokine has both immune activating and immune regulating properties. For example, IL-2 appears critical for the growth of T_R cells, and it has been proposed that one of the key features of IL-2 is to expand T_R cells [31]. However, a patient with CD25 deficiency was found to have relatively normal percentages of Foxp3⁺ cells in the peripheral blood, although CD4 cells from this patient failed to produce IL-10 *in vitro*, raising the possibility that CD25 deficiency results in defective function of T_R cells [16]. In support of this, studies have shown that T_R cells utilized CD25 as a cytokine sink that promotes apoptosis in a Bim-dependent manner in effector cells [15;32]. In addition, IL-2 has been shown to be critical for the generation of memory CD8 cells, which may help to explain why individuals lacking CD25 exhibit difficulties controlling chronic herpetic viruses [33].

Deficiency in STAT5b, one of two STAT5 protein, leads to a syndrome of immune deficiency with autoimmunity since signaling through the IL-2 receptor requires the signal transducer and activator of transcription protein 5 (STAT5) [34;35]. Growth failure is also observed since STAT5 is involved in growth hormone signaling. Most patients with these defects also develop pulmonary disease that is described as interstitial lymphocytic pneumonia, although whether this represents an autoimmune phenomenon or a response to infectious episodes is unclear. These infants also suffer from autoimmune diseases such as autoimmune thrombocytopenia and hemolytic anemia, eczema, and idiopathic arthritis implicating a defect in immune regulation similar to what is seen in CD25 deficiency [34;35]. This is partly explained by a low percentage of Foxp3⁺ T_R in these individuals as well as decreased suppressive ability of Tregs [34;35].

Defects in Tregs function

It has been known for some time that deficiency of IL-10 results in inflammatory bowel disease in mice, highlighting the suppressive nature of this cytokine [36]. Recently it has been described that IL-10 receptor (IL-10R) defects result in a syndrome characterized by early onset fistulizing colitis and folliculitis in humans [37]. IL-10 is an important cytokine in the function of T_R as demonstrated by conditional knockouts of IL-10 using a Foxp3-Cre protein to delete IL-10 in T_R cells [38]. These mice suffer from the early onset of inflammatory bowel disease similar to mice with complete deficiency in IL-10. This is further supported by studies with IL-10 reporter animals that show that in the gut Foxp3⁺ T_R cells are a predominant cell type expressing IL-10 [39;40]. However, Foxp3⁻ CD4⁺ cells also express IL-10 in this location and this may help to explain why the disease in Foxp3-Cre/IL-10 mice was delayed compared to IL-10 deficient animals [38]. An even more severe form of inflammatory bowel disease is incurred upon deletion of the IL-10R in murine T_R cells, resulting in a dysregulated Th17 cell response to gut flora. This experimental murine model indicates a critical role of IL-10R signaling in T_R cells in amplifying the regulatory effects of IL-10 produced by both T_R cells and effector T cells. It also suggests that T_R cells may be the locus of action of IL-10R deficiency in human subjects [20**].

X-linked lymphoproliferative disease type 2

Recently, defects in the anti-apoptotic protein x-linked inhibitor of apoptosis (xIAP) was shown to account for a second cause of X-linked lymphoproliferative syndrome [41]. These individuals were detected based on lymphoproliferative disease in males in response to Epstein-Barr Virus (EBV) infection. XLP1 results from defects in Slam associated protein (SAP) an important protein required for the activation of NK and cytotoxic lymphocytes, which likely accounts for the increased susceptibility to EBV infections [42]. xIAP binds caspase 3 and caspase 9 and prevents their activation, thus inhibiting apoptosis [43–45]. How these functions translate into increased susceptibility to EBV infection is unclear.

One interesting feature of xIAP deficiency is an increased susceptibility to inflammatory colitis, occurring in about 17% of patient [46]. Colitis is not seen in XLP1 deficiency. We have described a patient with early onset, aggressive fistulizing colitis that was found to have a novel mutation in xIAP detected by whole exome sequencing [47]. The etiology of the colitis in these individuals is unclear, but affected individuals have low percentages of T_R cells, perhaps due to excessive apoptosis of these cells [41;47]. In addition, xIAP has been recently implicated in signaling to NOD2, potentially explaining the early onset IBD that can occur in these individuals [48;49].

Deficiency in Ora1/Stim1

During T cell activation, release of intracellular calcium stores activates calcium release activated calcium channels (CRAC channels) that results in the influx of extracellular calcium which is critical to T cell activation [50–52]. ORA1 and STIM1 are two components of CRAC channels, and defects in these proteins cause severe combined immunodeficiency characterized by profound susceptibility to bacterial, viral and fungal infections [53]. In addition, deficiency of Stim1 also presents with autoimmune hemolytic anemia, autoimmune thrombocytopenia, and hypergammaglobulinemia [53]. Although autoimmunity was not reported in Ora1 deficiency, hypergammaglobulinemia with defective specific antibody production was reported. Lymphocyte numbers were normal, but there was an increase in CD4 lymphocytes expressing the memory marker CD45RO, suggesting immune dysregulation [54].

Autosomal dominant hyper IgE syndrome (AD-HIES)

AD-HIES, caused by mutations in STAT3, is a primary immunodeficiency with diverse clinical manifestations including eczema, recurrent skin and lung infections, and bone and teeth abnormalities [55;56]. Several studies have demonstrated a defect in the generation of TH17 CD4 T cells in HIES, a consequence of the critical function of STAT3 in signaling via cytokines receptors that instruct Th17 differentiation, including IL-6 and IL-21 receptors [57–60]. STAT3 is also critical for signaling via the IL-10 receptor, and defects in STAT3 may render target cells resistant to IL-10 produced by T_R cells [61]. In addition, recent data has demonstrated that defective signaling via the IL-10 receptor has been linked to impaired generation of tolerogenic DCs and defective formation of iTreg cells [19*]. Decreased iTreg formation, or blunted responsiveness of target cells to T_R cell derived IL-10 may contribute to mucosal inflammation in AD-HIES.

Mechanisms of autoimmunity in PIDs

The above observations demonstrate that primary immune deficiencies are associated with significant autoimmune manifestations. Several mechanisms can be invoked to explain this paradoxical observation. One feature of several of the above discussed PIDs is the observation of the expansion of autoreactive clones of T cells and resulting oligoclonality.

Omenn syndrome, a primary immunodeficiency presenting with increased susceptibility to infections, failure to thrive with diarrhea, early onset rash, and high IgE levels is a clear example. Omenn syndrome occurs due to hypomorphic mutations in the recombinase activating genes (RAG) resulting in defective TCR rearrangement and the emergence of oligoclonal T cells that expand in the periphery and display a memory phenotype [62;63]. Why this occurs is unclear, but the concept of homeostatic proliferation can be considered. This phenomenon shows that in lymphopenic environment, naïve lymphocytes will expand utilizing low affinity TCR contacts and cytokines, in particular IL-7 [64;65]. One function of T_R cells is to control this homeostatic proliferation of lymphocytes, as shown in mouse models where transfer of naïve CD4 cells into a lymphopenic animals results in inflammatory bowel disease and other autoimmune phenomenon [66]. Interestingly, T_R cells express low levels of CD127, the IL-7 receptor binding subunit, and it's possible that in lymphopenic environments, T_R cells have a competitive disadvantage compared to effector T cells [67].

In addition, recent work has demonstrated that Omenn syndrome is associated with defective thymic expression of the autoimmune regulator (AIRE), likely due to a complex interplay between lymphocytes, LT- α , and thymic stroma [68;69]. It is possible that any disease with defective T cell development and T cell lymphopenia could result in defective AIRE expression. AIRE deficiencies causes autoimmune polyendocrinopathy, candidiasis, and ectodermal dystrophy (APECED) due to defective expression of peripheral antigens in the thymus, a process that is critical to the deletion of autoreactive lymphocytes [70;71]. Similarly, studies on T_R receptor diversity have demonstrated that T_R cells express a highly diverse repertoire that is distinctive from that of conventional T cells [72]. This diverse repertoire is likely critical to the generation of a diverse population of T_R cells that see self as well as non-self antigens which are necessary for these cells to be activated in the periphery and inhibit T cell responses. The expression of peripheral antigens in the thymus by AIRE is likely critical to the generation of a diverse repertoire of T_R cells, and patients with AIRE deficiency have been shown to have decreased numbers, impaired suppressive function and altered repertoire of T_R cells [73]. When T cell receptor diversity is limited, such as in Omenn syndrome, thymic Foxp3⁺ cells may be absent [74]. However, this is not the entire answer since other patients with Omenn syndrome were found to have a relatively normal percentage of Foxp3⁺ cells as well as a normal mRNA levels of Foxp3 in peripheral blood [75;76].

Although decreased numbers of T_R cells has been described in primary immune deficiencies, it is also likely that impaired function of T_R cells contributes to the autoimmunity seen in these disorders. For example Wiskott-Aldrich syndrome (WAS) is a rare X-linked syndrome consisting of thrombocytopenia, eczema, recurrent infections, autoimmunity, and defective function of T_R [77;78]. WAS and other immunodeficiency disorders, such as Stim1/Ora1 deficiency, are associated with defective IL-2 production [77;79;80]. Paracrine IL-2 is critical for the expansion and function of T_R cells, since these cells express high levels of CD25 but low levels of the IL-7 receptor, and these cells do not express IL-2 unlike most T cells. Failure to produce IL-2 in these disorders may prevent T_R cell expansion and expression of immunosuppressive factors, ineffective inhibition of effector T cells, and resulting autoimmunity. In support of this, incubation of T_R cells defective in WASP with IL-2 corrects the suppressive defects of these cells [77].

Conclusion and Perspective

A critical role for T_R cell deficiency/dysfunction has emerged in recent studies on autoimmunity associated with PIDs. The mechanisms by which T_R cell deficiency develops in PID and its precise role in the autoimmune phenomena associated with these disorders

will require further studies involving human subjects and experimental animal models. Monitoring of T_R cell recovery and function post-therapy, including transplant and gene therapy, would be one important end measuring the success of those interventions.

Reference List

1. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol.* 2005; 6:345–352. [PubMed: 15785760]
2. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. *Nat Immunol.* 2005; 6:331–337. [PubMed: 15785758]
3. Chatila TA. Role of regulatory T cells in human diseases. *Journal of Allergy and Clinical Immunology.* 2005; 116:949–959. [PubMed: 16275360]
4. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.[comment]. *Nature Immunology.* 2003; 4:330–336. [PubMed: 12612578]
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3.[comment]. *Science.* 2003; 299:1057–1061. [PubMed: 12522256]
6. Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. *Immunity.* 2004; 21:267–277. [PubMed: 15308106]
7. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF- β Induction of Transcription Factor Foxp3. *J Exp Med.* 2003; 198:1875–1886. [PubMed: 14676299]
8. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting Edge: TGF- β Induces a Regulatory Phenotype in CD4+CD25- T Cells through Foxp3 Induction and Down-Regulation of Smad7. *J Immunol.* 2004; 172:5149–5153. [PubMed: 15100250]
9. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. *Nat Immunol.* 2005; 6:1219–1227. [PubMed: 16244650]
10. Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, Ziegelbauer J, Yassai M, Li SH, Relland LM, Wise PM, Chen A, Zheng YQ, Simpson PM, Gorski J, Salzman NH, Hessner MJ, Chatila TA, Williams CB. A Requisite Role for Induced Regulatory T Cells in Tolerance Based on Expanding Antigen Receptor Diversity. *Immunity.* 2011 This recent report demonstrates that iT_R and nT_R cells cooperate in immune regulation, and express divergent TCR repertoires.
11. Haribhai D, Lin W, Edwards B, Ziegelbauer J, Salzman NH, Carlson MR, Li SH, Simpson PM, Chatila TA, Williams CB. A central role for induced regulatory T cells in tolerance induction in experimental colitis. *J Immunol.* 2009; 182:3461–3468. [PubMed: 19265124]
12. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. *Proc Natl Acad Sci US A.* 2006; 103:6659–6664.
13. Rubtsov YP, Nieuwe RE, Josefowicz S, Li L, Darce J, Mathis D, Benoist C, Rudensky AY. Stability of the regulatory T cell lineage in vivo. *Science.* 2010; 329:1667–1671. [PubMed: 20929851]
14. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. *Nat Immunol.* 2009; 10:1000–1007. [PubMed: 19633673]
15. Barron L, Dooks H, Hoyer KK, Kuswanto W, Hofmann J, O’Gorman WE, Abbas AK. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. *J Immunol.* 2010; 185:6426–6430. [PubMed: 21037099]
16. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10

expression from CD4 lymphocytes. *J Allergy Clin Immunol.* 2007; 119:482–487. [PubMed: 17196245]

17. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. *PNAS.* 2004; 101:10398–10403. [PubMed: 15235129]
18. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. *Int Immunol.* 2004; 16:1391–1401. [PubMed: 15351783]
19. Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, Agematsu K, Yamada M, Kawamura N, Ariga T, Tsuge I, Nonoyama S, Karasuyama H, Minegishi Y. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. *J Exp Med.* 2011; 208:235–249. This report demonstrates that STAT3 mutations in AD-HIES compromise IL-10 signaling and the formation of tolerogenic dendritic cells and induced T_R cells. [PubMed: 21300911]
20. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. *Immunity.* 2011; 34:566–578. This report demonstrates that ablation of IL-10R in murine T_R cells results in failure regulate Th17 responses and a phenotype of severe colitis that mirrors the human IL-10R deficiency. [PubMed: 21511185]
21. Nakamura K, Kitani A, Strober W. Cell Contact-dependent Immunosuppression by CD4+CD25+ Regulatory T Cells Is Mediated by Cell Surface-bound Transforming Growth Factor {beta}. *J Exp Med.* 2001; 194:629–644. [PubMed: 11535631]
22. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med.* 2007; 204:1257–1265. [PubMed: 17502665]
23. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity.* 2004; 21:589–601. [PubMed: 15485635]
24. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature.* 2007; 450:566–569. [PubMed: 18033300]
25. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome.[comment]. *Journal of Clinical Investigation.* 2000; 106:R75–R81. [PubMed: 11120765]
26. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nature Genetics.* 2001; 27:20–21. [PubMed: 11137993]
27. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurf, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nature Genetics.* 2001; 27:68–73. [PubMed: 11138001]
28. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *Journal of Immunology.* 1995; 155:1151–1164.
29. Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. *Proc Natl Acad Sci U S A.* 1997; 94:3168–3171. [PubMed: 9096364]
30. McMurchy AN, Gillies J, Allan SE, Passerini L, Gambineri E, Roncarolo MG, Bacchetta R, Levings MK. Point mutants of forkhead box P3 that cause immune dysregulation,

polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. *J Allergy Clin Immunol*. 2010; 126:1242–1251. [PubMed: 21036387]

31. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat Immunol*. 2005; 6:1142–1151. [PubMed: 16227984]
32. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. *Nat Immunol*. 2007; 8:1353–1362. [PubMed: 17982458]
33. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. *Nature*. 2006; 441:890–893. [PubMed: 16778891]
34. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, Ornani A, Paz R, Rivarola MA, Zelazko M, Belgorosky A. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. *Pediatrics*. 2006; 118:e1584–e1592. [PubMed: 17030597]
35. Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, Teper A, Gaillard M, Heinrich J, Krensky AM, Rosenfeld RG, Lewis DB. Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. *J Immunol*. 2006; 177:2770–2774. [PubMed: 16920911]
36. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell*. 1993; 75:263–274. [PubMed: 8402911]
37. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hatscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med*. 2009; 361:2033–2045. [PubMed: 19890111]
38. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR Jr, Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity*. 2008; 28:546–558. [PubMed: 18387831]
39. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, Weaver CT. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. *Nat Immunol*. 2007; 8:931–941. [PubMed: 17694059]
40. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galan JE, Harhaj E, Flavell RA. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. *Immunity*. 2006; 25:941–952. [PubMed: 17137799]
41. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint BG, Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. *Nature*. 2006; 444:110–114. [PubMed: 17080092]
42. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E, Buckler AJ, Wise C, Ashley J, Lovett M, Valentine MB, Look AT, Gerald W, Housman DE, Haber DA. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. *Proc Natl Acad Sci U S A*. 1998; 95:13765–13770. [PubMed: 9811875]
43. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y, Alnemri ES. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. *Nature*. 2001; 410:112–116. [PubMed: 11242052]
44. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES, Shi Y. Structural basis of caspase-7 inhibition by XIAP. *Cell*. 2001; 104:769–780. [PubMed: 11257230]
45. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, Salvesen GS. Structural basis for the inhibition of caspase-3 by XIAP. *Cell*. 2001; 104:791–800. [PubMed: 11257232]
46. Pachlopnik SJ, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, Kanegane H, Lopez-Granados E, Mejstrikova E, Pellier I, Galicier L, Galambrun C, Barlogis V, Bordigoni P, Fourmaintraux A, Hamidou M, Dabadie A, Le Deist F, Haerynck F, Ouachee-Chardin M, Rohrlisch P, Stephan JL, Lenoir C, Rigaud S, Lambert N, Milili M, Schiff C, Chapel H, Picard C,

- de Saint BG, Blanche S, Fischer A, Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). *Blood*. 2011; 117:1522–1529. [PubMed: 21119115]
47. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. *Genet Med*. 2011; 13:255–262. [PubMed: 21173700]
 48. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. *Immunity*. 2009; 30:789–801. [PubMed: 19464198]
 49. Krieg A, Correa RG, Garrison JB, Le Negrato G, Welsh K, Huang Z, Knoefel WT, Reed JC. XIAP mediates NOD signaling via interaction with RIP2. *Proc Natl Acad Sci US A*. 2009; 106:14524–14529.
 50. Oh-hora M, Rao A. Calcium signaling in lymphocytes. *Curr Opin Immunol*. 2008; 20:250–258. [PubMed: 18515054]
 51. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. *Nature*. 2006; 443:230–233. [PubMed: 16921383]
 52. Feske S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol*. 2007; 7:690–702. [PubMed: 17703229]
 53. Picard C, McCarl CA, Papolos A, Khalil S, Luthy K, Hivroz C, Ledeist F, Rieux-Laucat F, Rechavi G, Rao A, Fischer A, Feske S. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. *N Engl J Med*. 2009; 360:1971–1980. [PubMed: 19420366]
 54. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, Hogan PG, Lewis RS, Daly M, Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature*. 2006; 441:179–185. [PubMed: 16582901]
 55. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature*. 2007; 448:1058–1062. [PubMed: 17676033]
 56. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B. STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med*. 2007; 357:1608–1619. [PubMed: 17881745]
 57. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature*. 2008; 452:773–776. [PubMed: 18337720]
 58. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Janniere L, Fieschi C, Stephan JL, Boileau C, Lyonnet S, Jondeau G, Cormier-Daire V, Le Merrer M, Hoarau C, Lebranchu Y, Lortholary O, Chandesaris MO, Tron F, Gambineri E, Bianchi L, Rodriguez-Gallego C, Zitnik SE, Vasconcelos J, Guedes M, Vitor AB, Marodi L, Chapel H, Reid B, Roifman C, Nadal D, Reichenbach J, Caragol I, Garty BZ, Dogu F, Camcioglu Y, Gulle S, Sanal O, Fischer A, Abel L, Stockinger B, Picard C, Casanova JL. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. *J Exp Med*. 2008; 205:1543–1550. [PubMed: 18591412]
 59. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J Exp Med*. 2008; 205:1551–1557. [PubMed: 18591410]
 60. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, Zhu Q, Jansson AF, Barboza J, Schimke LF, Leppert MF, Getz MM, Seger RA, Hill HR, Belohradsky BH, Torgerson TR, Ochs HD. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. *J Allergy Clin Immunol*. 2008; 122:181–187. [PubMed: 18602572]

61. Melillo JA, Song L, Bhagat G, Blazquez AB, Plumlee CR, Lee C, Berin C, Reizis B, Schindler C. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. *J Immunol.* 2010; 184:2638–2645. [PubMed: 20124100]
62. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, Gatta LB, Ochs HD, Schwarz K, Notarangelo LD, Vezzoni P, Spanopoulou E. Partial V(D)J recombination activity leads to Omenn syndrome. *Cell.* 1998; 93:885–896. [PubMed: 9630231]
63. Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. *J Allergy Clin Immunol.* 2008; 122:1082–1086. [PubMed: 18992930]
64. Surh CD, Sprent J. Homeostasis of naive and memory T cells. *Immunity.* 2008; 29:848–862.
65. Lenz DC, Kurz SK, Lemmens E, Schoenberger SP, Sprent J, Oldstone MB, Homann D. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. *Proc Natl Acad Sci U S A.* 2004; 101:9357–9362. [PubMed: 15197277]
66. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *Journal of Experimental Medicine.* 1999; 190:995–1004. [PubMed: 10510089]
67. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St GB, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J Exp Med.* 2006; 203:1701–1711. [PubMed: 16818678]
68. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, Notarangelo LD. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. *Blood.* 2009; 114:105–108. [PubMed: 19414857]
69. Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, Sediva A, Marrella V, Villa A, Fischer A, Notarangelo LD, Badolato R. AIRE deficiency in thymus of 2 patients with Omenn syndrome. *J Clin Invest.* 2005; 115:728–732. [PubMed: 15696198]
70. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. *Nat Genet.* 1997; 17:399–403. [PubMed: 9398840]
71. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the aire protein. *Science.* 2002; 298:1395–1401. [PubMed: 12376594]
72. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. *Nat Immunol.* 2006; 7:401–410. [PubMed: 16532000]
73. Kekalainen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, Pontynen N, Talvensaari K, Perheentupa J, Miettinen A, Arstila TP. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *J Immunol.* 2007; 178:1208–1215. [PubMed: 17202386]
74. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, Notarangelo LD. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. *Blood.* 2009; 114:105–108. [PubMed: 19414857]
75. Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, Vairo D, Plebani A, Giliani S, Vezzoni P, Facchetti F, Porta F, Notarangelo LD, Villa A, Badolato R. Defect of regulatory T cells in patients with Omenn syndrome. *J Allergy Clin Immunol.* 2010; 125:209–216. This report demonstrates severe reduction in numbers and function of Foxp3+ T cells in patients with Omenn's syndrome. [PubMed: 20109747]
76. Somech R, Simon AJ, Lev A, Dalal I, Spirer Z, Goldstein I, Nagar M, Amariglio N, Rechavi G, Roifman CM. Reduced central tolerance in Omenn syndrome leads to immature self-reactive oligoclonal T cells. *J Allergy Clin Immunol.* 2009; 124:793–800. [PubMed: 19767069]
77. Maillard MH, Cotta-de-Almeida V, Takeshima F, Nguyen DD, Michetti P, Nagler C, Bhan AK, Snapper SB. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. *J Exp Med.* 2007; 194:381–391.

78. Marangoni F, Trifari S, Scaramuzza S, Panaroni C, Martino S, Notarangelo LD, Baz Z, Metin A, Cattaneo F, Villa A, Aiuti A, Battaglia M, Roncarolo MG, Dupre L. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. *J Exp Med*. 2007; 199:369–380.
79. Adriani M, Aoki J, Horai R, Thornton AM, Konno A, Kirby M, Anderson SM, Siegel RM, Candotti F, Schwartzberg PL. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. *Clin Immunol*. 2007; 124:41–48. [PubMed: 17512803]
80. Oh-hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, Chung W, Prakriya M, Feske S, Rao A. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. *Nat Immunol*. 2008; 9:432–443. [PubMed: 18327260]

Key points

- Defects in regulatory T cell generation and/or function are important contributors to autoimmunity in Primary immunodeficiency diseases
- Defective generation of thymus-derived “natural” regulatory T cells is a feature of Omenn Syndrome due to hypomorphic RAG1/2 gene mutations
- Impaired generation of “induced” regulatory T cells, derived de novo from peripheral, conventional T cells has been recognized in the hyper IgE syndrome.
- Human genetic defects in the IL-10/IL-10 receptor system, critically important for regulatory T cell function at mucosal surfaces, are associated with early-onset inflammatory bowel disease.
- Reconstitution of the regulatory T cell compartment is an important endpoint of definitive therapies for Primary immunodeficiency diseases, including stem cell transplants and gene therapy.

Table 1Proposed mechanisms of suppression by T_R cells. [15–24]

T _R derived factor	Mechanism of suppression	References
CD25	Competition with effector cells for IL-2 Utilization of IL-2 for cytokine expression. and growth	[15] [16]
CTLA-4	Competition with effector cells for CD80/CD86 Induction of indolamine deoxygenase in DCs	[17] [18]
IL-10	Inhibition of dendritic cells Promote survival/fitness of T _R cells	[19] [20]
TGF- β	Inhibition of effector T cells	[21]
CD39/CD73	Consumption of adenosine	[22]
Perforin/granzymes	Cytotoxicity of effector cells (T cells, DCs)	[23]
IL-35	Suppression of T cells	[24]

Table 2
Mechanism of immune dysregulation of recently described primary immune deficiencies.

Mechanism of immune dysregulation	Omenn	STIM1	WAS	STAT3	CD25	xIAP	STAT5b	IL10R	APECED	IPEX
Expansion of oligoclonal T cells	+									
Apoptosis/loss of T _R cells	+	+			+	+	+	+/-		+
Defective IL-2 expression/responsiveness		+	+		+		+			
Defective responsiveness to T _R suppression				+				+		
Defective suppression by T _R cells			+		+		+			
Defective AIRE expression in thymus	+								+	
	<div><div>Susceptibility to infections</div><div>Autoimmunity</div></div>									